{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:41Z","timestamp":1791849401317,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00181-y","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:33:41Z","timestamp":1791822821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding and clinical approach to early T-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6744-0412","authenticated-orcid":false,"given":"Hee Young","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"181_CR1","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","volume":"21","author":"JM Goldberg","year":"2003","unstructured":"Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616\u201322. https:\/\/doi.org\/10.1200\/JCO.2003.10.116.","journal-title":"J Clin Oncol"},{"key":"181_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s44313-025-00085-3","volume":"60","author":"H Kim","year":"2025","unstructured":"Kim H, Yoon SH, Kang S, et al. Improved survival in pediatric acute lymphoblastic leukemia through therapy intensification based on minimal residual disease and protocol-driven early response risk classification. Blood Res. 2025;60:40. https:\/\/doi.org\/10.1007\/s44313-025-00085-3.","journal-title":"Blood Res"},{"key":"181_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(08)60457-2.","journal-title":"Lancet"},{"key":"181_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373:1541\u201352. https:\/\/doi.org\/10.1056\/NEJMra1400972.","journal-title":"N Engl J Med"},{"key":"181_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(08)70314-0.","journal-title":"Lancet Oncol"},{"key":"181_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","volume":"15","author":"A Vora","year":"2014","unstructured":"Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15:809\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(14)70243-8.","journal-title":"Lancet Oncol"},{"key":"181_CR7","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood.2023020678","volume":"142","author":"BL Wood","year":"2023","unstructured":"Wood BL, Devidas M, Summers RJ, et al. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study. Blood. 2023;142:2069\u201378. https:\/\/doi.org\/10.1182\/blood.2023020678.","journal-title":"Blood"},{"key":"181_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P P\u00f6l\u00f6nen","year":"2024","unstructured":"P\u00f6l\u00f6nen P, Di Giacomo D, Seffernick AE, et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature. 2024;632:1082\u201391. https:\/\/doi.org\/10.1038\/s41586-024-07807-0.","journal-title":"Nature"},{"key":"181_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/hematology.2025000713","volume":"2025","author":"J Xu","year":"2025","unstructured":"Xu J, Teachey DT. Emerging genomic biomarkers in diagnosis and classification of T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2025;2025:262\u20139. https:\/\/doi.org\/10.1182\/hematology.2025000713.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"181_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1309\/AJCPMF03LVSBLHPJ","volume":"144","author":"MJ You","year":"2015","unstructured":"You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia\/lymphoma. Am J Clin Pathol. 2015;144:411\u201322. https:\/\/doi.org\/10.1309\/AJCPMF03LVSBLHPJ.","journal-title":"Am J Clin Pathol"},{"key":"181_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ajh.26144","volume":"96","author":"K Morita","year":"2021","unstructured":"Morita K, Jain N, Kantarjian H, et al. Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021;96:589\u201398. https:\/\/doi.org\/10.1002\/ajh.26144.","journal-title":"Am J Hematol"},{"key":"181_CR12","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"key":"181_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","volume":"482","author":"AS Duffield","year":"2023","unstructured":"Duffield AS, Mullighan CG, Borowitz MJ. International consensus classification of acute lymphoblastic leukemia\/lymphoma. Virchows Arch. 2023;482:11\u201326. https:\/\/doi.org\/10.1007\/s00428-022-03448-8.","journal-title":"Virchows Arch"},{"key":"181_CR14","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/2159-8290.CD-23-1452","volume":"14","author":"S Kimura","year":"2024","unstructured":"Kimura S, Park CS, Montefiori LE, et al. Biologic and clinical analysis of childhood gamma delta T-ALL identifies LMO2\/STAG2 rearrangements as extremely high risk. Cancer Discov. 2024;14:1838\u201359. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1452.","journal-title":"Cancer Discov"},{"key":"181_CR15","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood.2023022920","volume":"145","author":"P P\u00f6l\u00f6nen","year":"2025","unstructured":"P\u00f6l\u00f6nen P, Mullighan CG, Teachey DT. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood. 2025;145:1464\u201374. https:\/\/doi.org\/10.1182\/blood.2023022920.","journal-title":"Blood"},{"key":"181_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","volume":"156","author":"T Inukai","year":"2012","unstructured":"Inukai T, Kiyokawa N, Campana D, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children\u2019s Cancer Study Group Study L99-15. Br J Haematol. 2012;156:358\u201365. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08955.x.","journal-title":"Br J Haematol"},{"key":"181_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.12882","volume":"166","author":"K Patrick","year":"2014","unstructured":"Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166:421\u20134. https:\/\/doi.org\/10.1111\/bjh.12882.","journal-title":"Br J Haematol"},{"key":"181_CR18","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, et al. Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38:3282\u201393. https:\/\/doi.org\/10.1200\/JCO.20.00256.","journal-title":"J Clin Oncol"},{"key":"181_CR19","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107:2783\u201393. https:\/\/doi.org\/10.3324\/haematol.2022.280638.","journal-title":"Haematologica"},{"key":"181_CR20","doi-asserted-by":"publisher","first-page":"e70206","DOI":"10.1002\/hem3.70206","volume":"9","author":"G Cario","year":"2025","unstructured":"Cario G, Valsecchi MG, Conter V, et al. Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: prognostic factors in the context of modern risk-adapted therapy. HemaSphere. 2009;9:e70206. https:\/\/doi.org\/10.1002\/hem3.70206.","journal-title":"HemaSphere"},{"key":"181_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199\u2013209. https:\/\/doi.org\/10.1016\/S1470-2045(12)70600-9.","journal-title":"Lancet Oncol"},{"key":"181_CR22","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1200\/JCO.22.02705","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, de Groot-Kruseman H, Fiocco M, et al. Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups. J Clin Oncol. 2023;41:4130\u201342. https:\/\/doi.org\/10.1200\/JCO.22.02705.","journal-title":"J Clin Oncol"},{"key":"181_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606\u201315. https:\/\/doi.org\/10.1038\/leu.2017.265.","journal-title":"Leukemia"},{"key":"181_CR24","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1200\/JCO.22.02734","volume":"41","author":"D O'Connor","year":"2023","unstructured":"O\u2019Connor D, Demeulemeester J, Conde L, et al. The clinicogenomic landscape of induction failure in childhood and young adult T-cell acute lymphoblastic leukemia. J Clin Oncol. 2023;41:3545\u201356. https:\/\/doi.org\/10.1200\/JCO.22.02734.","journal-title":"J Clin Oncol"},{"key":"181_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood.2023023155","volume":"145","author":"RJ Summers","year":"2025","unstructured":"Summers RJ, Teachey DT, Hunger SP. How I treat ETP-ALL in children. Blood. 2025;145:43\u201352. https:\/\/doi.org\/10.1182\/blood.2023023155.","journal-title":"Blood"},{"key":"181_CR26","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077\u201384. https:\/\/doi.org\/10.1182\/blood-2011-03-338707.","journal-title":"Blood"},{"key":"181_CR27","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/leu.2017.136","volume":"31","author":"C Delgado-Martin","year":"2017","unstructured":"Delgado-Martin C, Meyer LK, Huang BJ, et al. JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31:2568\u201376. https:\/\/doi.org\/10.1038\/leu.2017.136.","journal-title":"Leukemia"},{"key":"181_CR28","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.21.02678","volume":"40","author":"DT Teachey","year":"2022","unstructured":"Teachey DT, Devidas M, Wood BL, et al. Children\u2019s Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022;40:2106\u201318. https:\/\/doi.org\/10.1200\/JCO.21.02678.","journal-title":"J Clin Oncol"},{"key":"181_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.transproceed.2025.02.029","volume":"57","author":"C Cai","year":"2025","unstructured":"Cai C, Kang H, Ke P, et al. Comparative analysis of treatment outcomes and prognostic factors in early T-precursor versus non-ETP acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation in adolescents and young adults. Transplant Proc. 2025;57:619\u201326. https:\/\/doi.org\/10.1016\/j.transproceed.2025.02.029.","journal-title":"Transplant Proc"},{"key":"181_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.15919","volume":"186","author":"TM Horton","year":"2019","unstructured":"Horton TM, Whitlock JA, Lu X, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group. Br J Haematol. 2019;186:274\u201385. https:\/\/doi.org\/10.1111\/bjh.15919.","journal-title":"Br J Haematol"},{"key":"181_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995\u20139. https:\/\/doi.org\/10.1182\/blood-2017-07-794214.","journal-title":"Blood"},{"key":"181_CR32","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144:2237\u201347. https:\/\/doi.org\/10.1182\/blood.2024024493.","journal-title":"Blood"},{"key":"181_CR33","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11:1440\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1465.","journal-title":"Cancer Discov"},{"key":"181_CR34","doi-asserted-by":"publisher","first-page":"e70549","DOI":"10.1002\/mco2.70549","volume":"6","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhou H, Mao L, et al. Venetoclax and homoharringtonine-based therapy exhibited a striking response in refractory\/relapsed early T-cell precursor acute lymphoblastic leukemia. MedComm (2020). 2020;6:e70549. https:\/\/doi.org\/10.1002\/mco2.70549.","journal-title":"MedComm (2020)"},{"key":"181_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho Y, Liu J, Hu J, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2:284\u201399. https:\/\/doi.org\/10.1038\/s43018-020-00167-4.","journal-title":"Nat Cancer"},{"key":"181_CR36","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125:1759\u201367. https:\/\/doi.org\/10.1182\/blood-2014-06-580480.","journal-title":"Blood"},{"key":"181_CR37","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1182\/blood.2025028985","volume":"146","author":"LE Montefiori","year":"2025","unstructured":"Montefiori LE, Iacobucci I, Gao Q, et al. Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia. Blood. 2025;146:2350\u20136. https:\/\/doi.org\/10.1182\/blood.2025028985.","journal-title":"Blood"},{"key":"181_CR38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang J, Li J, et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023;98:1898\u2013908. https:\/\/doi.org\/10.1002\/ajh.27094.","journal-title":"Am J Hematol"},{"key":"181_CR39","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39:3340\u201351. https:\/\/doi.org\/10.1200\/JCO.21.00389.","journal-title":"J Clin Oncol"},{"key":"181_CR40","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood.2025029299","volume":"146","author":"J Pan","year":"2025","unstructured":"Pan J, Zhao L, Zhang Y, et al. Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial. Blood. 2025;146:2745\u201357. https:\/\/doi.org\/10.1182\/blood.2025029299.","journal-title":"Blood"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00181-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:34:03Z","timestamp":1791848043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00181-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["181"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00181-y","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"64"}}